Literature DB >> 6444966

Functional effects of thymopoietin32-36 (TP5) on cytotoxic lymphocyte precursor units (CLP-U). I. Enhancement of splenic CLP-U in vitro and in vivo after suboptimal antigenic stimulation.

C Y Lau, G Goldstein.   

Abstract

Cytotoxic lymphocyte precursor units (CLP-U) were enumerated in the spleens of C57BL/6 mice 3 days after i.p. injections of synthetic thymopoietin32-36 (TP5). One hundred to 1000 ng TP5/mouse potentiated splenic CLP-U, this effect being detectable only after suboptimal allogeneic sensitization (with 1.2 x 10(5) mitomycin-C treated DBA cells). This elevation of CLP-U persisted in the injected mice for at least 14 days. Control peptide did not affect CLP-U. In vitro incubation of 0.01 to 0.1 ng/ml of TP5 with normal C57BL/6 spleen cells also enhanced CLP-U after suboptimal allogeneic stimulation; high concentrations of TP5 caused suppression of CLP-U and this was detectable with optimal sensitization conditions. Thus TP5, in vitro and in vivo, appears to regulate immune responsiveness and this regulation varies with TP5 dosage and with the immune stimulus.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6444966

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  Treatment of severe rheumatoid arthritis.

Authors:  V Wright
Journal:  Br Med J (Clin Res Ed)       Date:  1986-02-15

2.  Prevention of recurrences in frequently relapsing herpes labialis with thymopentin. A randomized double-blind placebo-controlled multicenter study.

Authors:  K Bolla; D Djawari; E M Kokoschka; J Petres; S Lidén; R Gonseth; P Amblard; M G Bernengo; J J Bonerandi; A Claudy
Journal:  Surv Immunol Res       Date:  1985

3.  The serum thymic factor (FTS). Chemical and biological aspects.

Authors:  J M Pleau; M Dardenne; J F Bach
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

4.  Thymopoietin and levamisole in chronic granulomatous inflammation.

Authors:  P A Thrower; A D Sedgwick; E R Smith; D A Willoughby; E C Huskisson
Journal:  Ann Rheum Dis       Date:  1983-02       Impact factor: 19.103

5.  Effect of thymopentin on the mortality and immune response after an experimental herpes simplex infection in mice.

Authors:  R Cappel; F de Cuyper; K De Neef; W Höbel; K Bolla
Journal:  Surv Immunol Res       Date:  1985

6.  In vitro influence of thymopentin on proliferative responses and phytohemagglutinin-induced interleukin 2 production in normal human lymphocyte cultures.

Authors:  J Duchateau; G Servais; R Cooman; H Collet; K Bolla
Journal:  Surv Immunol Res       Date:  1985

7.  Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.

Authors:  P Franchimont; K Bolla
Journal:  Surv Immunol Res       Date:  1985

8.  Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy.

Authors:  A Castells; J Terencio; A Ramirez; E Sundal; K Bolla
Journal:  Surv Immunol Res       Date:  1985

9.  In vitro induction of monoclonal antibody-defined T-cell markers in lymphocytes from immunodeficient children by synthetic serum thymic factor (FTS).

Authors:  M C Bene; G Faure; P Bordigoni; D Olive; J Duheille
Journal:  Clin Exp Immunol       Date:  1982-05       Impact factor: 4.330

10.  Effect of synthetic thymic humoral factor (THF-gamma 2) on T cell activities in immunodeficient ageing mice.

Authors:  C Goso; D Frasca; G Doria
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.